- Home
- JGH vs FHTX Comparison
JGH vs FHTX Comparison
Compare JGH & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JGH | FHTX |
|---|---|---|
| Founded | 2014 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 355.2M | 323.4M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | JGH | FHTX |
|---|---|---|
| Price | $12.82 | $4.27 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $11.50 |
| AVG Volume (30 Days) | 78.6K | ★ 133.6K |
| Earning Date | 01-01-0001 | 05-06-2026 |
| Dividend Yield | ★ 9.85% | N/A |
| EPS Growth | N/A | ★ 25.32 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $30,909,000.00 |
| Revenue This Year | N/A | $8.89 |
| Revenue Next Year | N/A | $20.13 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 36.75 |
| 52 Week Low | $11.80 | $3.27 |
| 52 Week High | $13.70 | $6.95 |
Technical Indicators
Market Signals| Indicator | JGH | FHTX |
|---|---|---|
| Relative Strength Index (RSI) | 58.31 | 46.73 |
| Support Level | $12.64 | $3.62 |
| Resistance Level | $12.92 | $5.82 |
| Average True Range (ATR) | 0.17 | 0.25 |
| MACD | 0.01 | 0.05 |
| Stochastic Oscillator | 86.67 | 69.00 |
Price Performance
Historical ComparisonAbout JGH Nuveen Global High Income Fund of Beneficial Interest
Nuveen Global High Income Fund operates as a diversified closed-end management investment company. Its investment objective is to provide a high level of current income. The Fund's securities include U.S. high-yield bonds; non-U.S. high-yield bonds from developed and emerging markets; and other income-producing investments such as preferred and convertible securities.
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909.